First National Bank of Omaha cut its position in Pfizer Inc. (NYSE:PFE) by 7.8% during the first quarter, Holdings Channel reports. The firm owned 106,598 shares of the biopharmaceutical company’s stock after selling 9,011 shares during the period. First National Bank of Omaha’s holdings in Pfizer were worth $3,862,000 as of its most recent filing with the SEC.
A number of other large investors have also modified their holdings of PFE. Norges Bank purchased a new position in Pfizer during the fourth quarter valued at approximately $2,219,532,000. Morgan Stanley boosted its holdings in Pfizer by 16.4% during the fourth quarter. Morgan Stanley now owns 53,610,111 shares of the biopharmaceutical company’s stock worth $1,973,389,000 after buying an additional 7,540,245 shares in the last quarter. Bank of New York Mellon Corp grew its position in Pfizer by 12.1% during the fourth quarter. Bank of New York Mellon Corp now owns 64,756,839 shares of the biopharmaceutical company’s stock valued at $2,383,700,000 after buying an additional 6,965,496 shares during the period. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in Pfizer in the fourth quarter valued at $162,707,000. Finally, Bank of Nova Scotia raised its position in shares of Pfizer by 113.1% in the first quarter. Bank of Nova Scotia now owns 7,816,581 shares of the biopharmaceutical company’s stock worth $283,193,000 after acquiring an additional 4,148,877 shares during the period. Institutional investors own 67.36% of the company’s stock.
PFE stock traded down $0.17 during midday trading on Friday, hitting $39.95. 21,144,784 shares of the company’s stock were exchanged, compared to its average volume of 31,508,297. Pfizer Inc. has a 1-year low of $31.61 and a 1-year high of $43.08. The company has a current ratio of 1.40, a quick ratio of 1.13 and a debt-to-equity ratio of 0.76. The stock has a market capitalization of $223.63 billion, a PE ratio of 25.77, a P/E/G ratio of 2.79 and a beta of 0.70. The business has a 50-day simple moving average of $38.47 and a two-hundred day simple moving average of $37.03.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 4th. The biopharmaceutical company reported $0.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.78 by $0.15. Pfizer had a return on equity of 24.88% and a net margin of 17.85%. The firm had revenue of $14.58 billion during the quarter, compared to the consensus estimate of $13.41 billion. During the same period last year, the company earned $0.80 EPS. The company’s quarterly revenue was up 44.6% on a year-over-year basis. As a group, research analysts expect that Pfizer Inc. will post 2.89 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 4th. Stockholders of record on Friday, May 7th will be issued a $0.39 dividend. The ex-dividend date is Thursday, May 6th. This represents a $1.56 annualized dividend and a dividend yield of 3.90%. Pfizer’s dividend payout ratio is currently 52.88%.
A number of equities analysts have issued reports on PFE shares. Berenberg Bank reiterated a “neutral” rating and set a $38.00 price target on shares of Pfizer in a research report on Tuesday, March 23rd. JPMorgan Chase & Co. lifted their price target on shares of Pfizer from $36.00 to $40.00 and gave the company a “neutral” rating in a research note on Wednesday, May 5th. TheStreet upgraded shares of Pfizer from a “c+” rating to a “b-” rating in a research report on Monday, May 3rd. Morgan Stanley lifted their target price on shares of Pfizer from $38.00 to $42.00 and gave the company an “equal weight” rating in a research report on Monday, May 17th. Finally, Barclays raised their price target on shares of Pfizer from $37.00 to $40.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 5th. Twelve research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $39.74.
In related news, SVP Jennifer B. Damico sold 2,500 shares of Pfizer stock in a transaction that occurred on Wednesday, May 5th. The shares were sold at an average price of $40.82, for a total value of $102,050.00. Following the completion of the sale, the senior vice president now owns 13,748 shares in the company, valued at approximately $561,193.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.08% of the company’s stock.
About Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.
Read More: Conference Calls
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).